Reviewing Impact of Emerging JAK Inhibitor Data

The panel of experts dissect findings around breaking JAK inhibitor data in myelofibrosis treatment.

EP: 1.Treatment Approaches for Myeloproliferative Neoplasms

EP: 2.Patient Case 1: Patient with Intermediate Risk Myelofibrosis

EP: 3.Review of COMFORT I and COMFORT II Trials

EP: 4.Expert Takeaways from COMFORT I and II Trial Results

EP: 5.Managing Treatment Strategy for Patient Who Previously Declined ASCT

EP: 6.Key Clinical Trials Highlighting JAK Inhibitors in Myelofibrosis Treatment

Now Viewing

EP: 7.Reviewing Impact of Emerging JAK Inhibitor Data

EP: 8.Treatment of Advanced Polycythemia Vera

EP: 9.Long-Term Outcomes with Ruxolitinib in Polycythemia Vera

EP: 10.PROUD-PV/CONTINUATION-PV Trials for Ropeginterferon Alfa-2b in Polycythemia Vera

EP: 11.MAJIC-PV Trial: Ruxolitinib vs Best Available Therapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Recent Videos